External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy

Medicine and Dentistry

• Polyacrylamide Gel Electrophoresis 100%
• Hepatocellular Carcinoma 60%
• Patient 33%
• Chronic Hepatitis B 20%
• Antivirus Agent 13%
• Albumin 13%
• Lamivudine 13%
• Entecavir 13%
• Tenofovir 13%
• High Risk Population 6%
• Follow up 6%
• Platelet 6%
• Antiviral Therapy 6%
• Age 6%
• Intermediate Risk Population 6%
• Decompensated Liver Cirrhosis 6%
• Low Risk Population 6%
• Gender 6%

Pharmacology, Toxicology and Pharmaceutical Science

• Liver Cell Carcinoma 60%
• Chronic Hepatitis B 20%
• Antivirus Agent 13%
• Albumin 13%
• Entecavir 13%
• Lamivudine 13%
• Tenofovir 13%
• Decompensated Liver Cirrhosis 6%

Immunology and Microbiology

• Hepatitis B 20%
• Tenofovir 13%
• Platelet Count 6%
• High Risk Population 6%
• Age 6%
• Intermediate Risk Population 6%
• Gender 6%
• Low Risk Population 6%